NEW YORK (360Dx) – Avisa Pharma is developing a drug and device combination technology that can provide information on bacterial infections from a patient's exhaled breath. The test takes less than 10 minutes, detecting pathogen metabolites in breath after a patient inhales a tracer drug from a nebulizer, and the firm is currently focused on developing assays for pneumonia and Clostridium dificile.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.